Medicine Recommendations

Treatment of schizophrenia in adults aged 18 and over

Primary insomnia in those over 55

Sleep problems in patients with dementia associated with Alzheimer’s

Colonis liquid 1mg/ml and 3mg tablets for all indications, including insomnia and jet lag

For the Treatment of Rapid Eye Movement (REM) Sleep Behaviour Disorder (RBD) in Parkinson’s Disease and Lewy Body Dementia

Adults with learning disabilities

Sleep disturbance in adults with ADHD

Sleep disorders in the blind

Adults with complex neurodevelopmental disorders that the specialist considers eligible

Children with learning disabilities

Children with ADHD

Children and adolescents with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome

Cerebral palsy

Children with complex neurodevelopmental disorders that the specialist considers eligible

Alzheimer's Dementia (NICE TA217)

NICE TA217 - Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease

MHRA Drug Safety Update - Memantine pump device (Ebixa): risk of medication errors

Short term use in anxiety

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Tablets 5mg, Injection 10mg/1mL, liquid 1mg/ml

Pain or cough

ADHD in children, adolescents and adults

NICE guideline NG87: Attention deficit hyperactivity disorder: diagnosis and management

Nausea associated with Acute Migraine

MHRA Drug Safety Update - Metoclopramide: risk of neurological adverse effects

Nausea and vomiting

Opioid-induced nausea and vomiting

Depressive illness

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Status Epilepticus

MHRA Drug Safety Update - Buccal midazolam (Buccolam▼): new authorised medicine for paediatric use

Status Epilepticus

Breathlessness

Care in the last weeks or days of life - Breathlessness in the last days of life AND Agitation/terminal restlessness in the last days of life

Palliative care emergencies - Seizures AND Anixolytic following major blood loss

Depressive illness

Depressive illness, social phobia

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Narcolepsy

MHRA Drug Safety Update - Modafinil: now restricted to narcolepsy

Pain

MHRA Drug Safety Update - Drugs and driving: blood concentration limits set for certain drugs

Breathlessness

Pain in the last weeks or days of life

Breathlessness in the last days of life

Pain